AcelRx Pharmaceuticals is a drug manufacturers-specialty & generic business based in the US. AcelRx Pharmaceuticals shares (ACRX) are listed on the NASDAQ and all prices are listed in US Dollars. AcelRx Pharmaceuticals employs 19 staff and has a trailing 12-month revenue of around $253,000.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $0.67 |
|---|---|
| 52-week range | $0.55 - $5.36 |
| 50-day moving average | $1.00 |
| 200-day moving average | $1.28 |
| Wall St. target price | $8.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-3.71 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.6707 from 2023-09-22
| 1 week (2023-09-15) | -27.10% |
|---|---|
| 1 month (2023-08-24) | -41.17% |
| 3 months (2023-06-23) | -39.03% |
| 6 months (2023-03-24) | -4.19% |
| 1 year (2022-09-23) | 179.46% |
|---|---|
| 2 years (2021-09-20) | N/A |
| 3 years (2020-09-24) | 1.49 |
| 5 years (2018-09-24) | 4.6 |
| Revenue TTM | $253,000 |
|---|---|
| Gross profit TTM | $-3,341,000 |
| Return on assets TTM | -33.27% |
| Return on equity TTM | -68.59% |
| Profit margin | 0% |
| Book value | $0.95 |
| Market Capitalization | $15 million |
TTM: trailing 12 months
We're not expecting AcelRx Pharmaceuticals to pay a dividend over the next 12 months.
AcelRx Pharmaceuticals's shares were split on a 1:20 basis on 25 October 2022. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your AcelRx Pharmaceuticals shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for AcelRx Pharmaceuticals shares which in turn could have impacted AcelRx Pharmaceuticals's share price.
Over the last 12 months, AcelRx Pharmaceuticals's shares have ranged in value from as little as $0.55 up to $5.362. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AcelRx Pharmaceuticals's is 0.2313. This would suggest that AcelRx Pharmaceuticals's shares are less volatile than average (for this exchange).
AcelRx Pharmaceuticals, Inc. , a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.